{
  "drug_id": "D010",
  "drug_name": "Juvencor",
  "indication": "Rare-G",
  "modality": "enzyme replacement",
  "mechanism": "gene expression silencer",
  "moa_short": "Reduces target mRNA to decrease protein expression.",
  "formulation": "vial for infusion",
  "route": "intravenous",
  "regimen": "3 mg/kg Q3W",
  "trial_id": "AMGN-D010-201",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Juvencor 3 mg/kg Q3W",
      "n": 177,
      "dose": "3 mg/kg Q3W"
    },
    {
      "name": "Placebo",
      "n": 178,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Rare-G with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Quality-of-life improvement at Week 12",
    "primary_effect": "LS mean difference -1.14 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.023196683403158475,
    "primary_ci": "[-1.54, -0.74]",
    "secondary_effect": "Met nominal significance in hierarchical testing",
    "discontinuation_rate_pct": 10.646290445348056
  },
  "safety": {
    "common_ae": [
      [
        "Headache",
        7.449957636858788
      ],
      [
        "Nausea",
        4.822930826494061
      ],
      [
        "Dizziness",
        3.1150463214423554
      ],
      [
        "Diarrhea",
        2.0
      ],
      [
        "Injection-site reaction",
        2.0
      ],
      [
        "Arthralgia",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 2.5261829977808627,
    "discontinuation_ae_rate_pct": 3.765320592290175,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.9",
  "doc_date": "2025-12-26"
}